SitemapImpressumDatenschutzerklärungdeutschenglish
MHH Logo

Publikationen Teilprojekt A2


[1] Baumgart J, Bintig W, Ngezahayo A, Willenbrock S, Murua Escobar H, Ertmer W, Lubatschowski H, Heisterkamp A (2008) Quantified femtosecond laser based opto-perforation of living GFSHR-17 and MTH53 a cells. Opt Express 16: 3021-3031.

[2] Willenbrock S, Braun O, Baumgart J, Lange S, Junghanss C, Heisterkamp A, Nolte I, Bullerdiek J, Murua Escobar H (2012b) TNF-alpha induced secretion of HMGB1 from non-immune canine mammary epithelial cells (MTH53A). Cytokine 57: 210-220.

[3] Sterenczak KA, Joetzke AE, Willenbrock S, Eberle N, Lange S, Junghanss C, Nolte I, Bullerdiek J, Simon D, Murua Escobar H (2010) High-mobility group B1 (HMGB1) and receptor for advanced glycation end-products (RAGE) expression in canine lymphoma. Anticancer Res 30: 5043-5048.

[4] Altmann S, Lange S, Pommerencke J, Murua Escobar H, Bullerdiek J, Nolte I, Freund M, Junghanss C (2008) High Mobility Group Box 1-Protein expression in canine haematopoietic cells and influence on canine peripheral blood mononuclear cell proliferative activity. Vet Immunol Immunopathol 126:367-372.

[5] Fitting J, Killian D, Junghanss C, Willenbrock S, Murua Escobar H, Lange S, Nolte I, Barth S, Tur MK (2011) Generation of recombinant antibody fragments that target canine dendritic cells by phage display technology. Vet Comp Oncol 9: 183-195.

[6] Petersen S, Soller JT, Wagner S, Richter A, Bullerdiek J, Nolte I, Barcikowski S, Murua Escobar H (2009) Co-transfection of plasmid DNA and laser-generated gold nanoparticles does not disturb the bioactivity of GFP-HMGB1 fusion protein. J Nanobiotechnology 7: 6.

[7] Baumgart J, Bintig W, Ngezahayo A, Lubatschowski H, Heisterkamp A (2010) Fs-laser-induced Ca2+ concentration change during membrane perforation for cell transfection. Opt Express 18: 2219-2229.

[8] Baumgart J, Kütemeyer K, Bintig W, Ngezahayo A, Ertmer W, Lubatschowski H, Heisterkamp A (2009) Repetition rate dependency of reactive oxygen species formation during femtosecond laserbased cell surgery. J Biomed Opt 14: 054040.

[9] Willenbrock S, Knippenberg S, Meier M, Hass R, Wefstaedt P, Nolte I, Murua Escobar H, Petri S (2012a) In vivo MRI of intraspinally injected SPIO-labelled human CD34+ cells in a transgenic mouse model of ALS. In Vivo 26: 31-38.

[10] Sterenczak KA, Meier M, Glage S, Meyer M, Willenbrock S, Wefstaedt P, Dorsch M, Bullerdiek J, Murua Escobar H, Hedrich H, Nolte I (2012) Longitudinal MRI contrast enhanced monitoring of early tumour development with manganese chloride (MnCl2) and superparamagnetic iron oxide nanoparticles (SPIOs) in a CT1258 based in vivo model of prostate cancer. BMC Cancer MS:1881886255644423, accepted for publication.

[11] Junghanss C, Rathsack S, Wacke R, Weirich V, Vogel H, Drewelow B, Mueller S, Altmann S, Freund M, Lange S (2012) Everolimus in combination with cyclosporin a as pre- and posttransplantation immunosuppressive therapy in nonmyeloablative allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 18: 1061-1068.

[12] Reichard M, Hovakimyan M, Wree A, Meyer-Lindenberg A, Nolte I, Junghans C, Guthoff R, Stachs O (2010) Comparative in vivo confocal microscopical study of the cornea anatomy of different laboratory animals. Curr Eye Res 35: 1072-1080.